Search research articles
Contact Us
Filters
Showing results (131-140 of 166) with videos related to
Page
of 17
Sort By:
European Urology
|
March 30, 2019
A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment
Benoit Peyronnet, Emma Mironska, Christopher Chapple, et al.
European Urology
|
November 28, 2012
Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial
Vik Khullar, Gerard Amarenco, Javier C Angulo, et al.
Neurourology and Urodynamics
|
March 16, 2012
What are the causes and consequences of bladder overdistension? ICI-RS 2011
Helmut Madersbacher, Linda Cardozo, Christopher Chapple, et al.
Advances in Therapy
|
July 9, 2017
Prevalence of Lower Urinary Tract Symptoms in China, Taiwan, and South Korea: Results from a Cross-Sectional, Population-Based Study
Christopher Chapple, David Castro-Diaz, Yao-Chi Chuang, et al.
Cell Transplantation
|
January 22, 2015
Regeneration of degenerated urinary sphincter muscles: improved stem cell-based therapies and novel imaging technologies
Bastian Amend, Martin Vaegler, Kerstin Fuchs, et al.
Journal of Clinical Pharmacology
|
April 13, 2018
Cardiovascular Safety of the β<sub>3</sub> -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial
William B White, Christopher Chapple, Christian Gratzke, et al.
European Urology Focus
|
October 20, 2023
A Retrospective Database Analysis to Investigate Treatment Patterns and Health Care Resource Utilisation in Patients who CYCLe AntiMuscarinics in ENgland (CYCLAMEN)
Jon Rees, Rodrigo Martins de Almeida, Mahmood Ali, et al.
Neurourology and Urodynamics
|
January 16, 2019
Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study
Elizabeth R Mueller, Rob van Maanen, Christopher Chapple, et al.
BJU International
|
July 12, 2008
A review of adherence to drug therapy in patients with overactive bladder
Ramandeep K Basra, Adrian Wagg, Christopher Chapple, et al.
BJU International
|
October 18, 2013
Validation of the bladder control self-assessment questionnaire (B-SAQ) in men
Arun Sahai, Christopher Dowson, Eduardo Cortes, et al.
Page
of 17
Search research articles
Search
Showing results (131-140 of 166) with videos related to
Sort By:
Page
of 17
European Urology
|
March 30, 2019
A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment
Benoit Peyronnet, Emma Mironska, Christopher Chapple, et al.
European Urology
|
November 28, 2012
Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial
Vik Khullar, Gerard Amarenco, Javier C Angulo, et al.
Neurourology and Urodynamics
|
March 16, 2012
What are the causes and consequences of bladder overdistension? ICI-RS 2011
Helmut Madersbacher, Linda Cardozo, Christopher Chapple, et al.
Advances in Therapy
|
July 9, 2017
Prevalence of Lower Urinary Tract Symptoms in China, Taiwan, and South Korea: Results from a Cross-Sectional, Population-Based Study
Christopher Chapple, David Castro-Diaz, Yao-Chi Chuang, et al.
Cell Transplantation
|
January 22, 2015
Regeneration of degenerated urinary sphincter muscles: improved stem cell-based therapies and novel imaging technologies
Bastian Amend, Martin Vaegler, Kerstin Fuchs, et al.
Journal of Clinical Pharmacology
|
April 13, 2018
Cardiovascular Safety of the β<sub>3</sub> -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial
William B White, Christopher Chapple, Christian Gratzke, et al.
European Urology Focus
|
October 20, 2023
A Retrospective Database Analysis to Investigate Treatment Patterns and Health Care Resource Utilisation in Patients who CYCLe AntiMuscarinics in ENgland (CYCLAMEN)
Jon Rees, Rodrigo Martins de Almeida, Mahmood Ali, et al.
Neurourology and Urodynamics
|
January 16, 2019
Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study
Elizabeth R Mueller, Rob van Maanen, Christopher Chapple, et al.
BJU International
|
July 12, 2008
A review of adherence to drug therapy in patients with overactive bladder
Ramandeep K Basra, Adrian Wagg, Christopher Chapple, et al.
BJU International
|
October 18, 2013
Validation of the bladder control self-assessment questionnaire (B-SAQ) in men
Arun Sahai, Christopher Dowson, Eduardo Cortes, et al.
Page
of 17